Brolucizumab
Red
Brand:
Nice TA:
672
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Eye
Background
1.1 Brolucizumab is recommended as an option for treating wet age-related
macular degeneration in adults, only if, in the eye to be treated:
- the best-corrected visual acuity is between 6/12 and 6/96
- there is no permanent structural damage to the central fovea
- the lesion size is less than or equal to 12 disc areas in greatest linear dimension and
- there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes).
It is recommended only if the company provides brolucizumab according to the
commercial arrangement.